Cytokine profiling, antibody titers determination and tumor neutralization assay were performed to evaluate the immunogenicity of the constructed vaccine candidates in inducing HER2/neu-specific humoral and cellular immune responses. The gene discussed is ERBB2; the disease is neoplasm.